Apoptosis in Health and Disease - Part B, Volume 126 in the Advances in Protein Chemistry and Structural Biology focuses on apoptotic responses in numerous conditions - from bacterial and parasite infections, to pathological states such as oxidative stress, pulmonary hypertension, and different cancer types, etc. In addition, the book provides therapeutic strategies for targeting apoptosis. These new advanced understandings are playing a major influence in drug discovery and the introduction of new therapies that target the cell death process.
Apoptosis, or programmed cell death, is the mechanism by which cells die either physiologically or pathologically. Vast research in apoptosis has advanced our understanding of basic physiological and pathological processes occurring in cells, organs and organisms, and its role in a number of diseases.
Donev
Apoptosis in Health and Disease - Part B jetzt bestellen!
Zielgruppe
<p>This volume would be of great interest to a very wide audience - protein chemists, molecular cell biologists, immunologists, structural biologists, computational biochemists, medical doctors, pharmacologists and other researchers working in the field of transport proteins and drug design. Articles published here would also be of a considerable benefit to medical, biology and pharmacology students specializing in this field. </p>
Weitere Infos & Material
Contributors in the volume include:
Santi Prasad Sinha Babu
Soundarapandian KANNAN
Soundarapandian KANNAN
Dayanidhi Raman
Gautam Sethi
Mohammad Abid
Pankaj Taneja
Anupam Bishayee
Harikumar KB
Natella Enukashvily
Sadhana R. Joshi
Ali Akbar Moosavi-Movahedi
Donev, Rossen
Rossen Donev received his PhD degree in 1999 from the Institute of Molecular Biology, Bulgarian Academy of Sciences. He did postdoctoral training at Imperial Cancer Research Fund, UK (renamed after the merger with Cancer Research Campaign to Cancer Research UK, London Research Institute) and Cardiff University. In 2007 he was awarded a New Investigator Grant Award from the Medical Research Council (UK) to establish himself as an independent Principle Investigator. In 2010 Dr. Donev was appointed Senior Lecturer at Swansea University. In 2016 Dr. Donev joined MicroPharm Ltd (UK) where currently he is Head of Research. He has published more than 60 research papers, chaired scientific meetings and given invited plenary talks. Rossen Donev has consulted on projects related to development of treatments for neurodevelopmental disorders and cancer therapies. He serves as Editor-in-Chief of the Advances in Protein Chemistry and Structural Biology and on editorial board of several other journals. His research interests include signaling pathways involved in neuropsychiatric disorders and tumor escape from the immune system, and development of therapeutic strategies for their treatment. More recently he has focused on development of immunotherapeutics for non-systemic applications.
